Zydus signs deal with Myriad Genetics

New Delhi: Zydus Lifesciences Ltd on Friday said it has signed an exclusive agreement with Myriad Genetics of US to launch cancer-risk assessment diagnostic tests in India. Under the agreement, Zydus will introduce MyRisk Hereditary Cancer Test, MyChoice HRD Plus, homologous recombination deficiency (HRD) test and Prolaris prostate cancer prognostic test to patients, clinicians, and healthcare systems across India, the company said in a regulatory filing. "This agreement marks a major step in expanding access to precision diagnostic tests for cancer treatment in India.